DORADO, PUERTO RICO / ACCESSWIRE / September 28, 2017 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB: PBSV), a compliance, project management, and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food, and allied products industries, today announced an update regarding operations following Hurricane Maria.

First and foremost, our personnel have been safely accounted for and many have returned to work in our Dorado office as we work towards resuming normal operations.

Pharma-Bio Serv’s corporate offices, assets, and laboratory in Puerto Rico appear to have not suffered any structural damage during Hurricane Maria and the Company expects minimal cleanup and recovery costs. Our laboratory is running on our diesel dependent generator, which was designed to support our lab systems and personnel. Resources are being acquired to provide additional backup capabilities and we are evaluating additional alternatives for power supply and access to diesel, which are the primary challenges for all Puerto Rico businesses during this recovery. We are also utilizing our recovery location in San Juan to quickly respond in the aftermath of the hurricane. In addition, our US, Spain, Ireland and South American divisions are fully operational and are providing assistance to the workforce in Puerto Rico. We are also evaluating the use of remote facilities in the US.

Most of our customers in Puerto Rico have been contacted and are in various stages of recovery. Although we likely will continue to feel the effects of the hurricane for the next few months, we believe we will begin placing some of our resources in customer locations as early as next week.

While Puerto Rico has clearly suffered tremendously from Hurricane Maria and much of the island’s infrastructure and communication networks are still greatly impaired, we will continue working aggressively on your behalf.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv is a compliance, project management, and technology transfer support consulting firm, headquartered in Puerto Rico, with operations in the U.S., Ireland, and Spain. Pharma-Bio Serv’s core business is FDA and other international regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic, Food and Allied Products industries. The Company’s services also include “Pharma Serv Academy,” a division that provides technical and regulatory standards seminars/training conducted by industry experts. The Company’s global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv’s management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv’s actual results or performance to differ materially from the forward-looking statements include those set forth in the “Risk Factors” section of Pharma-Bio Serv’s Annual Report on Form 10-K for the year ended October 31, 2016, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:

Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv, Inc.

ReleaseID: 476624

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adidas. (“Adidas” or the “Company”) (OTCQX: ADDYY) (OTCQX: ADDDF). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/addyy.

The investigation concerns whether Adidas and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 26, 2017, federal prosecutors unveiled fraud charges against 10 people associated with certain NCAA basketball programs, including four coaches and an Adidas executive. Prosecutors announced that they uncovered two related schemes, including one in which apparel executives, financial advisers and others bribed assistant college coaches to steer elite players to their programs, and a second in which players were allegedly bribed to enroll at schools sponsored by Adidas. On this news, Adidas’s share price fell $7.20, or 3.17%, to close at $220.00 on September 26, 2017.

If you are aware of any facts relating to this investigation, or purchased Adidas shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/addyy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 476608

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Top Ships Inc. (“Top Ships” or the “Company”) (NASDAQ: TOPS) for possible violations of federal securities laws from January 17, 2017 through August 22, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Top Ships shares during the Class Period, should contact the firm prior to the October 23, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, CEO Evangelos J. Pistiolis caused the Company to engage in a series of manipulative share issuance and sales transactions with Kalani Investments Limited (“Kalani”) through which Top Ships would sell its common shares and securities convertible into common shares to Kalani at a significant discount to market price and file registration statements so that Kalani could resell these shares into the market. When Kalani’s sales of Top Ships stock caused its share price to decline, the Company would reverse split the stock, causing a certain number of outstanding shares to be merged into a single share, and thereby raise the price of its stock. Then, the Company would again sell securities to Kalani, and the same pattern of transactions would ensue. While Top Ships was engaging in these transactions, the Company failed to disclose the true purpose of the transactions and related stock issuances and reverses – to finance related-party transactions and acquisitions that primarily benefited Mr. Pistiolis and his related companies, and otherwise funnel money to Company insiders. By August 2017, Top Ships, through Kalani, issued and sold into the market tens of millions of shares of its common stock, vastly diluting the Company’s existing shareholders. While Top Ships used the proceeds from these offerings to further enrich Mr. Pistiolis and his affiliates through various related-party transactions, the value of Top Ships’ common stock has fallen by more than 99%, which caused investors harm.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476619

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE: VSI) for possible violations of federal securities laws from March 1, 2017 through August 6, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Vitamin Shoppe shares during the Class Period, should contact the firm prior to the October 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that the Company’s ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was announced, Vitamin Shoppe’s stock price declined materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476620

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Health Insurance Innovations, Inc. (“Health Insurance Innovations” or the “Company”) (NASDAQ: HIIQ) for possible violations of federal securities laws between August 2, 2017 and September 11, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the November 10, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Health Insurance Innovations made false and/or misleading statements and/or failed to disclose: that the Company’s application for a third-party insurance administrators license with the Florida Office of Insurance Regulation was denied due partly to material errors and omissions; that the Florida Office of Insurance Regulation’s rejection of its application for a third-party insurance administrators license could result in loss of licenses in the other states; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was announced, shares of Health Insurance Innovation fell in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476621

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against The Advisory Board Company (“Advisory Board” or the “Company”) (NASDAQ: ABCO) for possible violations of federal securities laws from January 21, 2015 through February 23, 2016, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Advisory Board shares during the Class Period, should contact the firm by October 2, 2017, the lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Advisory Board made materially false and/or misleading statements, and/or failed to disclose, that there were severe integration problems associated with its acquisition of Royall and, as a consequence, the Company had no basis to increase the revenue guidance for Royall during the Class Period. When this information went public, Advisory Board’s stock price fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476613

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE: EVHC) for possible violations of federal securities laws from March 2, 2015 through July 21, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Envision shares during the Class Period, should contact the firm before the October 3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.

The Complaint states that throughout the Class Period, Envision made materially false and/or misleading statements, and/or failed to disclose material information, to investors. On July 24, 2017, The New York Times published an article reporting that hospitals associated with the Company’s subsidiary, EmCare Holdings, Inc., were disproportionately likely to engage in “surprise billing,” in which patients seeking treatment at in-network facilities were treated by out-of-network physicians and then billed at higher rates. When this news went public, Envision’s share price fell materially, which caused investors harm according to the lawsuit.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476614

LOS ANGELES, CA / ACCESSWIRE / September 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Applied Optoelectronics, Inc. (“Applied Optoelectronics” or the “Company”) (NASDAQ: AAOI) for possible violations of federal securities laws from July 13, 2017 through August 3, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Applied Optoelectronics shares during the Class Period, should contact the firm before October 4, 2017, the lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint states that during the Class Period, Applied Optoelectronics made false and/or misleading statements, and/or failed to disclose: that a major customer was decreasing its purchases of the Company’s 40G receivers; that the loss of this major customer’s business would have a severe negative impact on the Company’s financial performance; and that as a result, the Company’s public statements were materially false and misleading at all relevant times. When this news went public, Applied Optoelectronics’ stock price lowered materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 476615